Imlunestrant and Abemaciclib for the Treatment of Estrogen Receptor Positive Breast Cancer in Patients With Minimal Residual Disease, MIRI Trial

Clinical trial NCT07191717 · RECRUITING

Trial details

NCT number: NCT07191717
Sponsor: Jonsson Comprehensive Cancer Center
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Anatomic Stage I Breast Cancer AJCC v8 Anatomic Stage II Breast Cancer AJCC v8 Anatomic Stage III Breast Cancer AJCC v8 Invasive Breast Carcinoma Localized Estrogen Receptor-Positive Breast Carcinoma Localized Human Epidermal Growth Factor Receptor (HER2)-Negative Breast Carcinoma

Start date: 2026-05-18
Primary completion: 2030-04-30
Enrollment: 42

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.